Despite the recent privacy row with smartphones and other GPS enabled devices, a Wisconsin doctor is proposing use of an inhaler with built in global positioning system to track where and when asthma sufferers use their medication. By capturing data on inhaler usage, the doctor proposes that asthma sufferers can learn more about what triggers an attack and the medical community can learn more about this chronic condition.
Despite the recent privacy row with smartphones and other GPS enabled devices, a Wisconsin doctor is proposing use of an inhaler with built in global positioning system to track where and when asthma sufferers use their medication. By capturing data on inhaler usage, the doctor proposes that asthma sufferers can learn more about what triggers an attack and the medical community can learn more about this chronic condition. However, the use of such a device has privacy implications that need serious consideration.
For millions of people on a worldwide basis, asthma is no joke. An April 9, 2011 Economist article mentions that asthma affects more than 300 million people, almost 5% of the world’s population.
Editor’s note: Paul Barsch is an employee of Teradata. Teradata is a sponsor of The Smart Data Collective.
More Read
Scientists and the medical community have long pondered the question; ‘What triggers an asthma attack?’ Is it pollen, dust in the air, mold spores or other environmental factors? The key to learning the answer to this question is not only relevant for asthma sufferers themselves, but also society (and healthcare costs) as there are more than 500,000 asthma related hospital admissions every year.
In an effort to better understand factors behind asthma attacks, Dr. David Van Sickle, co-founded a company that makes an inhaler with GPS to track usage. Van Sickle once worked for the Centers for Disease Control (CDC), and he believes that with better data society can understand asthma in a deeper manner. By capturing data on asthma inhaler usage and then plotting the results with visualization tools, Van Sickle hopes that this information can be sent back to primary care physicians to help patients understand asthma triggers.
A better understanding of asthma makes sense for patients, health insurers and society at large. The Economist article notes that pilot studies of device usage thus far have resulted in basic understandings of asthma coming into question. However, there are surely privacy implications in the capture, management and use of this data, despite reassurances from the medical community that data will be anonymized and secured.
Should societal and patient benefits outweigh privacy concerns when it comes to tracking asthma patients? What do you think? I’d love to hear from you.
